Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Development and external validation of a dual-stage predictive model for self-reported physician-diagnosed chronic lung disease, asthma, and lung cancer in Chinese adults.

Created on 05 Jul 2026

Authors

Xuefen Cui, Xueying Sun

Published in

Scientific reports. Jul 04, 2026. Epub Jul 04, 2026.

Abstract

Chronic respiratory diseases represent a leading cause of global mortality, yet robust prediction tools integrating onset risk and long-term prognosis for aging populations remain scarce. Here, we present a dual-stage predictive framework for self-reported physician-diagnosed chronic lung disease, asthma, and lung cancer using two nationally representative Chinese cohorts. By systematically evaluating 96 fully linear models, we identified distinct pathophysiological drivers for disease onset versus mortality. While disease susceptibility was primarily driven by non-pulmonary comorbidities and systemic inflammation, survival outcomes were predominantly determined by functional exhaustion and frailty indicators. The two models achieved decent external validation in an oldest-old cohort. These findings elucidate a critical shift from disease accumulation to functional decline in respiratory pathology, providing an interpretable, evidence-based tool for early risk stratification and precise clinical intervention in elderly patients.

PMID:
42401586
Bibliographic data and abstract were imported from PubMed on 05 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 2
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement